Piper Sandler Reaffirms Jazz Pharmaceuticals (JAZZ) Price Target Ahead of Trial Data

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ranks among the most undervalued NASDAQ stocks to buy now. Piper Sandler reaffirmed its Overweight rating and $147 price target for Jazz Pharmaceuticals plc ...
TipRanks on MSN

Jazz Pharmaceuticals announces new evidence, Phase 4 data on Xywav

Jazz Pharmaceuticals (JAZZ) announced new real-world evidence and Phase 4 data reinforcing the value of Xywav oral solution treatment outcomes in ...
Seeking Alpha

Jazz Pharmaceuticals projects late Q4 zanidatamab Phase III data, signals leadership transition and updates 2025 guidance

Bruce C. Cozadd, Chairman and CEO, announced Renee D. Gala's appointment as President and CEO effective August 11, stating "I'm confident Renee is the right leader to build on Jazz's momentum and ...
Nasdaq

Jazz Presents Overall Survival & Longer Data From Trial Of Zanidatamab In Biliary Tract Cancer

(RTTNews) - Jazz Pharmaceuticals plc (JAZZ) announced long-term follow-up results, including the first-ever overall survival or OS findings, from the Phase 2b HERIZON-BTC-01 clinical trial of ...
Nasdaq

Jazz Pharma Reports Positive Topline Data From Phase 3 IMforte Maintenance Study In ES-SCLC

(RTTNews) - Jazz Pharmaceuticals plc (JAZZ) Tuesday announced positive top-line results from the Phase 3 IMforte study in adults with extensive-stage small cell lung cancer (ES-SCLC). The study is ...